Kairaba Pharmaceuticals Limited Pharmaceutical Import Profile — Gambia (DGFT 2022–2026)

Name: Kairaba Pharmaceuticals Limited Pharmaceutical Import Records from India — 2 Products, $650.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kairaba Pharmaceuticals Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $650.7K Trade | TransData Nexus

Kairaba Pharmaceuticals Limited

Pharmaceutical Importer · Gambia · Combination Drugs Focus · $650.7K Total Trade · DGFT Verified

Kairaba Pharmaceuticals Limited is a pharmaceutical importer based in Gambia with a total trade value of $650.7K across 2 products in 1 therapeutic categories. Based on 15 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Kairaba Pharmaceuticals Limited sources from 6 verified Indian suppliers, with Medinomics Health Care Private Limited accounting for 24.7% of imports.

Kairaba Pharmaceuticals Limited — Import Portfolio & Supplier Network

Kairaba Pharmaceuticals Limited import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Kairaba Pharmaceuticals Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medinomics Health Care Private Limited	$304.1K	33	24.7%
Socomed Pharma Private Limited	$302.8K	35	24.6%
Syncom Formulations India Limited

What Formulations Does Kairaba Pharmaceuticals Limited Import?

Formulation	Value	Ships
Super peptee tablets cyproheptadine TAB	$57.0K	2
Dyclosa 50 tablets new artwork eachenteric coated tablet cont. diclofenac sodium BP 50	$50.0K	1
Dyclosa 50 tablets (new with hologram (multicolor shipper Each enteric coated tablet contains diclofenac	$47.6K	1
Aniclox CAPS 500MG. ampicillin and cloxacillin capsules 1498000 CAPS @ usd 0.02949 x 100 x 10 x 10 t 01 x 60 x	$44.2K	1
Cortim tablets (white round tablet (eachuncoated tablet cont.trimethoprim BP 80MG,sulfamethoxazole BP 400	$34.8K	1
Killpane tablets acetylsalicylic acid	$32.5K	1
Killpane tablests acetylsalicylic acid300 MG+ paracetamol 150MG +caffeine 30 MG	$32.4K	1
Other, containing antimalarial active	$32.0K	2
Othercontaining antimalarial active principles described in sub-heading note 2to this chapter	$30.1K	1
Other. paracetamol 325 MG +diclofenac sodium 50 MG + caffeine 30 MG tablets newzibo extra. (pieces = Pack of 10 x 1 x	$27.2K	2
Other. peladol extra. (paracetamol 325 MG + diclofenac sodium 50 MG + caffeine 30 MG tablets) (pieces - packs of 20 x	$25.4K	3
Other: peladol extra (paracetamol 325 MG+diclofenac sodium 50 MG + caffeine 30MG tablets) (pieces = Pack of 20 x 1 x	$24.4K	3
Kva ibuprofen tablets BP 400MG eachsugar coated tablet contain ibuprofen bp400 MG	$23.5K	1
Anirelief cold tablets	$22.9K	2
Cortim tablets round shape Each uncoated tablet cont.trimethoprim BP 80 mgsulfamethoxazole BP 400 MG	$20.6K	1

Kairaba Pharmaceuticals Limited imports 128 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetylsalicylic	Combination Drugs	$355.7K	8	6.6%	4
2	Salicylic	Combination Drugs	$295.0K	7	1.8%	9

Kairaba Pharmaceuticals Limited imports 2 pharmaceutical products across 1 categories into Gambia totaling $650.7K.

Kairaba Pharmaceuticals Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kairaba Pharmaceuticals Limited is a prominent pharmaceutical importer and distributor based in Banjul, The Gambia. Established in 1991, the company has been a key player in the Gambia pharmaceutical sector, focusing on the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Operating under the license number MCA/IMP/0002/2025, Kairaba Pharmaceuticals Limited is headquartered at 61 Kairaba Avenue, K.S.M.D., The Gambia. (mca.gm)

The company plays a pivotal role in the Gambia pharmaceutical distribution network, serving as a primary wholesaler and distributor. By sourcing a diverse range of pharmaceutical products, Kairaba Pharmaceuticals Limited ensures the availability of essential medications across the country, thereby contributing significantly to the healthcare infrastructure of The Gambia.

2Distribution Network

Kairaba Pharmaceuticals Limited operates a centralized distribution model from its headquarters in Banjul. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network capable of serving the entire Gambian market. The company's strategic location in Banjul facilitates efficient access to both domestic and international markets, enhancing its logistical operations.

3Industry Role

In the Gambia pharmaceutical supply chain, Kairaba Pharmaceuticals Limited functions primarily as a wholesaler and distributor. By importing a wide array of pharmaceutical products, the company ensures that essential medications are accessible to pharmacies, hospitals, and healthcare facilities throughout the country. This role is crucial in maintaining the stability and reliability of the pharmaceutical supply chain in The Gambia.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Kairaba Pharmaceuticals Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Kairaba Pharmaceuticals Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a select group of Indian suppliers. The company's total import value from India stands at $651,000 USD, distributed across 15 shipments. The top five products imported include Acetylsalicylic acid ($356,000 USD), Salicylic acid ($295,000 USD), and other combination drugs, collectively accounting for 100% of the company's imports.

This concentrated sourcing approach may present risks related to supply chain disruptions, currency fluctuations, and dependency on a limited number of suppliers. However, it also indicates a strategic choice to maintain consistent product quality and pricing. The stability of these supplier relationships is crucial for Kairaba Pharmaceuticals Limited's operational continuity.

2Supply Chain Resilience

The resilience of Kairaba Pharmaceuticals Limited's supply chain is closely tied to its reliance on a limited number of Indian suppliers. The company's import data reveals a total of 15 shipments from six unique suppliers, with the top five suppliers accounting for the majority of the import value. This suggests a potential vulnerability to supply chain disruptions, such as production delays or geopolitical issues affecting India.

To enhance supply chain resilience, Kairaba Pharmaceuticals Limited could consider diversifying its supplier base and establishing relationships with additional manufacturers. This strategy would mitigate risks associated with over-reliance on a few suppliers and ensure a more robust supply chain capable of adapting to unforeseen challenges.

Importing Pharmaceuticals into Gambia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Gambia

1Regulatory Authority & Framework

The Medicines Control Agency (MCA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products in The Gambia. Established under the Medicines and Related Products Act, 2014, the MCA is responsible for ensuring the safety, efficacy, and quality of medicines available in the country. (mca.gm)

Key legislation governing pharmaceutical imports includes the Medicines and Related Products Act, 2014, which outlines the requirements for the registration and importation of medicines. The MCA enforces strict guidelines to prevent the entry of substandard or counterfeit medicines into the Gambian market. These regulations are designed to protect public health and maintain the integrity of the pharmaceutical supply chain.

2Import Licensing & GMP

Importers in The Gambia must obtain an import permit from the MCA before bringing pharmaceutical products into the country. This process involves submitting an application that includes detailed information about the products, their manufacturers, and intended use. The MCA charges a non-refundable processing fee for import permit applications. (mca.gm)

The MCA recognizes Good Manufacturing Practice (GMP) certifications from reputable authorities, including the European Union (EU), World Health Organization (WHO), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certifications from these recognized bodies to guarantee the quality and safety of imported medicines.

Kairaba Pharmaceuticals Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Kairaba Pharmaceuticals Limited's focus on combination drugs, particularly Acetylsalicylic acid and Salicylic acid, aligns with the therapeutic needs of the Gambian population. These products are commonly used for pain relief, anti-inflammatory purposes, and cardiovascular health, addressing prevalent health concerns in the country. The company's import strategy is driven by market demand for these essential medications, ensuring their availability to meet public health needs.

2Sourcing Profile

Kairaba Pharmaceuticals Limited's sourcing strategy is centered on importing generic drugs from India, a country known for its robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a focus on ready-to-use products that can be distributed efficiently within The Gambia. India's competitive pricing and adherence to international quality standards make it a strategic partner for Kairaba Pharmaceuticals Limited's procurement needs.

3Market Positioning

Based on its product mix, Kairaba Pharmaceuticals Limited primarily serves the wholesale distribution segment of the Gambian market. By importing and distributing a range of pharmaceutical products, the company ensures that essential medications are accessible to pharmacies, hospitals, and healthcare facilities across the country. This role is crucial in maintaining the stability and reliability of the pharmaceutical supply chain in The Gambia.

Seller's Guide — How to Become a Supplier to Kairaba Pharmaceuticals Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Kairaba Pharmaceuticals Limited, particularly in the supply of combination drugs and other essential medications. The company's concentrated sourcing pattern suggests potential gaps in its current supplier base, which could be addressed by establishing partnerships with additional Indian manufacturers. By offering high-quality products that meet the MCA's regulatory standards, new suppliers can position themselves as valuable partners to Kairaba Pharmaceuticals Limited and expand their presence in the Gambian market.

2Requirements & Qualifications

Indian exporters seeking to supply Kairaba Pharmaceuticals Limited and the Gambian market must ensure that their products comply with the MCA's regulatory requirements. This includes obtaining GMP certifications from recognized authorities such as the EU, WHO, or PIC/S. Additionally, products must meet labeling standards, including English language requirements and inclusion of the manufacturer's name and address. Importers are also required to provide samples for testing before importation to verify compliance with these standards. (op.gov.gm)

How to Approach

Frequently Asked Questions — Kairaba Pharmaceuticals Limited

What products does Kairaba Pharmaceuticals Limited import from India?

Kairaba Pharmaceuticals Limited imports 2 pharmaceutical products across 1 categories. Top imports: Acetylsalicylic ($355.7K), Salicylic ($295.0K).

Who supplies pharmaceuticals to Kairaba Pharmaceuticals Limited from India?

Kairaba Pharmaceuticals Limited sources from 6 verified Indian suppliers. The primary supplier is Medinomics Health Care Private Limited (24.7% of imports, $304.1K).

What is Kairaba Pharmaceuticals Limited's total pharmaceutical import value?

Kairaba Pharmaceuticals Limited's total pharmaceutical import value from India is $650.7K, based on 15 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Kairaba Pharmaceuticals Limited focus on?

Kairaba Pharmaceuticals Limited imports across 1 categories. The largest: Combination Drugs (100.0%).

Get Full Kairaba Pharmaceuticals Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.